Microbot Medical Received Confirmation For The Commencement Of Its CE Mark Approval Process During The First Half Of 2024
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical has received confirmation for the commencement of its CE Mark approval process during the first half of 2024. The company's designated Notified Body will conduct audits for ISO 13485 certification to ensure compliance with the QMS requirements of the EU MDR. The full CE Mark approval process for the LIBERTY® Robotic Surgical System will be carried out in parallel with the FDA regulatory process.
October 24, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Microbot Medical's CE Mark approval process for the LIBERTY® Robotic Surgical System is set to commence in the first half of 2024. This process will run in parallel with the FDA regulatory process.
The news of the commencement of the CE Mark approval process for Microbot Medical's LIBERTY® Robotic Surgical System is directly related to the company and its operations. This could potentially open up the European market for the company, which would be a significant development. Therefore, this news is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100